Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.34 |
| ▸ | PLD2 | O14939 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514062 | 0.83 | OPRM1 (0.39) | OPRM1HTR6PARP1PARP2CHRM1 | |
| SCHEMBL29198301 | 0.81 | GPR119 (0.48) | OPRM1PARP1CHRM1HSD11B1CALCRL | |
| SCHEMBL30825650 | 0.80 | OPRM1 (0.40) | OPRM1HTR6PARP1PARP2CHRM1 | |
| SCHEMBL22869588 | 0.77 | ALDH1A1 (0.47) | OPRM1CHRM1HSD11B1DRD2CALCRL | |
| SCHEMBL22605719 | 0.74 | HTR6 (0.47) | OPRM1HTR6CHRM1HSD11B1DRD2 | |
| SCHEMBL3243652 | 0.74 | OPRM1 (0.62) | OPRM1CHRM1DRD2 | |
| SCHEMBL28505346 | 0.74 | OPRM1 (0.47) | OPRM1PARP1PARP2CHRM1HSD11B1 | |
| SCHEMBL4306275 | 0.74 | CHRM1 (0.57) | OPRM1PARP1PARP2CHRM1HSD11B1 | |
| SCHEMBL3243793 | 0.74 | HSD11B1 (0.53) | OPRM1CHRM1HSD11B1DRD2 | |
| SCHEMBL30870578 | 0.74 | OPRM1 (0.44) | OPRM1PARP1PARP2CHRM1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| CN-112074511-A | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2020-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | OPRM1 1598/4885HTR6 3128/4885PARP1 1799/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | OPRM1 1245/4885HTR6 2765/4885PARP1 1824/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | OPRM1 1245/4885HTR6 2765/4885PARP1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.